Request a Rep
Order NowLILETTA® RESOURCES FOR YOU:
ORDERING AND PRICING INFORMATION
Contact Allergan Direct at 1-855-LILETTA (7am CST to 7pm CST) for ordering and pricing information
ORDER THROUGH A SPECIALTY PHARMACY
| Specialty Pharmacy | Contact Information |
|---|---|
| Accredo® | 1.866.759.1557 |
| CVS Caremark® | 1.855.438.2574 |
LILETTA ACCESSCONNECTSM:24/7 REAL-TIME SUPPORT
Order LILETTA directly from AbbVie and manage your inventory
Gain access to patient records for on-demand results
Visit LILETTAAccessConnect.com for more information.
LILETTA PATIENT SAVINGS PROGRAM®:RESOURCES FOR YOUR ELIGIBLE PATIENTS
ELIGIBLE PATIENTS MAY BE ABLE TO SAVE ON THE LILETTA PRODUCT WITH THE LILETTA PATIENT SAVINGS PROGRAM®
Your commercially insured patients may be eligible to participate in the LILETTA Patient Savings Program®.
Patients can learn more at LILETTAcard.com.
Please note that the LILETTA Patient Savings Program® only applies to the cost of the product. It does not apply to the cost of insertion or medical examination.
*Depending on insurance coverage, eligible patients pay $100, then save up to a maximum of $750, for the first LILETTA® product. Offer applies to product only, and does not apply to costs associated with medical examination or product administration. Check with your pharmacist or healthcare provider for your copay discount. Patient out-of-pocket expense may vary. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Please see full LILETTA Patient Savings Program® Terms, Conditions, and Eligibility Criteria here.
MEDICINES360 PARTNERSHIP: A UNIQUE COLLABORATION
AbbVie (the maker of LILETTA®) has a groundbreaking partnership with Medicines360®, a non-profit women’s health pharmaceutical company, to expand access to LILETTA regardless of income or insurance coverage.
AbbVie is investing in innovative programs and solutions that facilitate access in both the public and private sectors.
Medicines360 invests its proceeds in advocacy, education, and additional product and partnership development to further its mission in the U.S. and globally.
HELP:
Purchasing:
For information regarding pricing and ordering LILETTA
Benefits Investigations:
For help with patient benefits investigations and billing and coding
LILETTA Patient Savings Program®:
For information on eligibility criteria, enrollment process, and terms and conditions
Adverse Events/Medical Information:
To report any Adverse Events or to request additional medical information on LILETTA. You may also call our direct Medical Information line at: 1.800.678.1605
Product Quality:
To report any product quality complaints
Request a Field Sales Representative:
To request a visit from a field sales representative
DOWNLOADABLE RESOURCES:
Placement
Practice
- 1. This offer is available to patients with commercial prescription insurance coverage for a valid prescription of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg at the time the prescription is filled or after the product is administered to the patient.
- 2. This offer is not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs (including any state pharmaceutical assistance programs), or private indemnity or HMO insurance plans that reimburse you for the entire cost of your prescription drugs. Patients may not use this offer if they are Medicare-eligible and enrolled in an employer-sponsored health plan or medical or prescription drug benefit program for retirees. This offer is not valid for cash-paying patients. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be eligible to use the LILETTA Patient Savings Program.
- 3. Depending on your insurance coverage, eligible patients pay $100, then save up to a maximum of $750, for the first LILETTA® product. Check with your pharmacist or healthcare provider for your copay discount. Patient out-of-pocket expense may vary.
- 4. Each card is valid for one LILETTA® prescription, which must be filled or administered to the patient before the program. Savings requests and required supporting documentation must be submitted to www.LILETTAcard.com or faxed to 888.683.4991 within 180 days after the prescription is filled and the product is administered to the patient.
- 5. AbbVie reserves the right to rescind, revoke, or amend this offer without notice.
- 6. Offer good only in the USA, including Puerto Rico, at participating pharmacies or healthcare providers. Patients residing in or receiving treatment in certain states may not be eligible.
- 7. Void where prohibited by law, taxed, or restricted.
- 8. Patients may not seek reimbursement for value received from LILETTA Savings Program from any third-party payers.
- 9. This card is not transferable. The selling, purchasing, trading, or counterfeiting of this card is prohibited by law.
- 10. This card has no cash value and may not be used in combination with any other discount, coupon, rebate, free trial, or similar offer for the specified prescription.
- 11. This offer is not health insurance.
- 12. By redeeming this card, you acknowledge that you are an eligible patient and that you understand and agree to comply with the terms and conditions of this offer.
For patient assistance, please call 1.855.706.4508 Monday through Friday 9 AM—8 PM ET (except holidays). For healthcare provider or pharmacist assistance, please call the 24 hr/7 day a week help desk at 1.866.242.9104.
Program managed by ConnectiveRx on behalf of AbbVie.
LILETTA® is a sterile, levonorgestrel-releasing intrauterine system indicated for prevention of pregnancy for up to 8 years. The system should be replaced after 8 years if continued use is desired.
Use of LILETTA is contraindicated in women with the following: pregnancy; for use as post-coital contraception; congenital or acquired uterine anomaly, including fibroids, that distorts the uterine cavity and would be incompatible with correct intrauterine system (IUS) placement; known or suspected breast cancer or other hormone-sensitive cancer, now or in the past; known or suspected uterine or cervical neoplasia; acute liver disease or liver tumor; untreated acute cervicitis or vaginitis, including lower genital tract infections (eg, bacterial vaginosis), until infection is controlled; postpartum endometritis or infected abortion in the past 3 months; unexplained uterine bleeding; a current IUS; acute pelvic inflammatory disease (PID); conditions increasing susceptibility to pelvic infection; or hypersensitivity to any component of LILETTA.
Use LILETTA with caution after careful assessment in women with coagulopathy or taking anticoagulants; migraine, focal migraine with asymmetrical visual loss, or other symptoms indicating transient cerebral ischemia; exceptionally severe or frequent headache; marked increase of blood pressure; or severe arterial disease such as stroke or myocardial infarction. Consider removing LILETTA if the following arise during use: uterine or cervical malignancy or jaundice. Because irregular bleeding/spotting is common during the first months of LILETTA use, exclude endometrial pathology (polyps or cancer) prior to the insertion of LILETTA in women with persistent or uncharacteristic bleeding. If the threads are not visible or are significantly shortened, they may have broken or retracted into the cervical canal or uterus. If LILETTA is displaced (eg, expulsed or perforated the uterus), remove it.
If pregnancy should occur with LILETTA in place, remove the IUS because leaving it in place may increase the risk of spontaneous abortion and preterm labor. Removal or manipulation may result in pregnancy loss. Evaluate women for ectopic pregnancy because the likelihood of a pregnancy being ectopic is increased. Tell women about the signs of ectopic pregnancy and associated risks, including loss of fertility. Women with a history of ectopic pregnancy, tubal surgery, or pelvic infection have a higher risk of ectopic pregnancy.
Insertion of LILETTA is contraindicated in the presence of known or suspected PID or endometritis. IUSs have been associated with an increased risk of PID, most likely due to organisms being introduced into the uterus during insertion. One woman diagnosed with PID and two women diagnosed with endometritis developed the infection within a week of insertion. One endometritis case was diagnosed at 39 days after insertion. The remaining 11 cases of PID and endometritis were diagnosed more than 6 months after insertion, including one at 30 days after IUS removal. Counsel women who use LILETTA to notify a healthcare provider if they develop lower abdominal or pelvic pain, fever, chills, unusual or malodorous discharge, unexplained bleeding, genital lesions or sores, or dyspareunia. PID and endometritis are often associated with sexually transmitted infections (STIs); LILETTA does not protect against STIs, including HIV. PID or endometritis may be asymptomatic but still result in tubal damage and its sequelae. Inform women about the possibility of PID or endometritis and that these infections can cause tubal damage leading to ectopic pregnancy or infertility, or infrequently can necessitate hysterectomy, or cause death.
Spotting and irregular or heavy bleeding may occur during the first 3 to 6 months. Periods may become shorter and/or lighter thereafter. Cycles may remain irregular, become infrequent, or even cease. Consider pregnancy if menstruation does not occur within 6 weeks of the onset of previous menstruation. If a significant change in bleeding develops during prolonged use, conduct diagnostic tests to assess possible endometrial pathology.
Some serious complications with IUSs like LILETTA are sepsis, perforation, and expulsion. Severe infection or sepsis, including Group A streptococcal sepsis (GAS), have been reported following insertion of LNG-releasing IUSs. Aseptic technique during insertion of LILETTA is essential to minimize serious infections such as GAS.
Perforation (total or partial, including penetration/embedment of LILETTA in the uterine wall or cervix) may occur, most often during insertion, although the perforation may not be detected until sometime later. Perforation may also occur at any time during use. Perforation may reduce contraceptive efficacy. If perforation is suspected, locate and remove LILETTA as soon as possible. Surgery may be required. Delayed detection or removal of LILETTA in case of perforation may result in migration outside the uterine cavity, adhesions, peritonitis, intestinal perforations, intestinal obstruction, abscesses, and erosion of adjacent viscera. The risk of perforation is increased if inserted in women who have fixed retroverted uteri, are postpartum, or are lactating. Delay LILETTA insertion a minimum of 4 weeks or until uterine involution is complete following a delivery or a second-trimester abortion.
Partial or complete expulsion of LILETTA may occur, resulting in the loss of contraceptive protection. Expulsion risk is increased when inserted immediately after delivery; it appears to be increased with insertions after second-trimester abortion, based on limited data. Remove a partially expelled LILETTA. If expulsion has occurred, a new LILETTA may be inserted when there is reasonable certainty the patient is not pregnant.
Ovarian cysts may occur and are generally asymptomatic, but may be accompanied by pelvic or abdominal pain or dyspareunia. Evaluate persistent ovarian cysts.
In the LILETTA clinical trial, the most common adverse reactions (≥5% users) were vulvovaginal mycotic infections (20.2%), vaginal bacterial infections (19.2%), acne (15.5%), nausea or vomiting (10.5%), headache (10.1%), breast tenderness or pain (10.1%), abdominal discomfort or pain (10.0%), dyspareunia (9.6%), anxiety (9.6%), depression (9.1%), pelvic discomfort or pain (8.7%), dysmenorrhea (7.3%), mood changes (6.5%), back pain (6.5%), increased weight (6.1%), and vaginal discharge (5.8%).
Teach patients to recognize and immediately report signs or symptoms of the aforementioned conditions. Consider evaluating patients 4 to 6 weeks after LILETTA insertion and during routine care, or more often if clinically indicated. Check threads during each evaluation.
Please see full Prescribing Information
References: 1. LILETTA (levonorgestrel-releasing intrauterine system) 52 mg [prescribing information]. Irvine, CA: Allergan USA, Inc., and San Francisco, CA: Medicines360. 2. Mirena (levonorgestrel-releasing intrauterine system) 52 mg [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc. 3. Kyleena (levonorgestrel-releasing intrauterine system) 19.5 mg [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc. 4. Skyla (levonorgestrel-releasing intrauterine system) 13.5 mg [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc. 5. Data on file. Medicines360: San Francisco, CA.
Use of LILETTA is contraindicated in women with the following: pregnancy; for use as post-coital contraception; congenital or acquired uterine anomaly, including fibroids, that distorts the uterine cavity and would be incompatible with correct intrauterine system (IUS) placement; known or suspected breast cancer or other hormone-sensitive cancer, now or in the past; known or suspected uterine or cervical neoplasia; acute liver disease or liver tumor; untreated acute cervicitis or vaginitis, including lower genital tract infections (eg, bacterial vaginosis), until infection is controlled; postpartum endometritis or infected abortion in the past 3 months; unexplained uterine bleeding; a current IUS; acute pelvic inflammatory disease (PID); conditions increasing susceptibility to pelvic infection; or hypersensitivity to any component of LILETTA.
Use LILETTA with caution after careful assessment in women with coagulopathy or taking anticoagulants; migraine, focal migraine with asymmetrical visual loss, or other symptoms indicating transient cerebral ischemia; exceptionally severe or frequent headache; marked increase of blood pressure; or severe arterial disease such as stroke or myocardial infarction. Consider removing LILETTA if the following arise during use: uterine or cervical malignancy or jaundice. Because irregular bleeding/spotting is common during the first months of LILETTA use, exclude endometrial pathology (polyps or cancer) prior to the insertion of LILETTA in women with persistent or uncharacteristic bleeding. If the threads are not visible or are significantly shortened, they may have broken or retracted into the cervical canal or uterus. If LILETTA is displaced (eg, expulsed or perforated the uterus), remove it.
If pregnancy should occur with LILETTA in place, remove the IUS because leaving it in place may increase the risk of spontaneous abortion and preterm labor. Removal or manipulation may result in pregnancy loss. Evaluate women for ectopic pregnancy because the likelihood of a pregnancy being ectopic is increased. Tell women about the signs of ectopic pregnancy and associated risks, including loss of fertility. Women with a history of ectopic pregnancy, tubal surgery, or pelvic infection have a higher risk of ectopic pregnancy.
Insertion of LILETTA is contraindicated in the presence of known or suspected PID or endometritis. IUSs have been associated with an increased risk of PID, most likely due to organisms being introduced into the uterus during insertion. One woman diagnosed with PID and two women diagnosed with endometritis developed the infection within a week of insertion. One endometritis case was diagnosed at 39 days after insertion. The remaining 11 cases of PID and endometritis were diagnosed more than 6 months after insertion, including one at 30 days after IUS removal. Counsel women who use LILETTA to notify a healthcare provider if they develop lower abdominal or pelvic pain, fever, chills, unusual or malodorous discharge, unexplained bleeding, genital lesions or sores, or dyspareunia. PID and endometritis are often associated with sexually transmitted infections (STIs); LILETTA does not protect against STIs, including HIV. PID or endometritis may be asymptomatic but still result in tubal damage and its sequelae. Inform women about the possibility of PID or endometritis and that these infections can cause tubal damage leading to ectopic pregnancy or infertility, or infrequently can necessitate hysterectomy, or cause death.
Spotting and irregular or heavy bleeding may occur during the first 3 to 6 months. Periods may become shorter and/or lighter thereafter. Cycles may remain irregular, become infrequent, or even cease. Consider pregnancy if menstruation does not occur within 6 weeks of the onset of previous menstruation. If a significant change in bleeding develops during prolonged use, conduct diagnostic tests to assess possible endometrial pathology.
Some serious complications with IUSs like LILETTA are sepsis, perforation, and expulsion. Severe infection or sepsis, including Group A streptococcal sepsis (GAS), have been reported following insertion of LNG-releasing IUSs. Aseptic technique during insertion of LILETTA is essential to minimize serious infections such as GAS.
Perforation (total or partial, including penetration/embedment of LILETTA in the uterine wall or cervix) may occur, most often during insertion, although the perforation may not be detected until sometime later. Perforation may also occur at any time during use. Perforation may reduce contraceptive efficacy. If perforation is suspected, locate and remove LILETTA as soon as possible. Surgery may be required. Delayed detection or removal of LILETTA in case of perforation may result in migration outside the uterine cavity, adhesions, peritonitis, intestinal perforations, intestinal obstruction, abscesses, and erosion of adjacent viscera. The risk of perforation is increased if inserted in women who have fixed retroverted uteri, are postpartum, or are lactating. Delay LILETTA insertion a minimum of 4 weeks or until uterine involution is complete following a delivery or a second-trimester abortion.
Partial or complete expulsion of LILETTA may occur, resulting in the loss of contraceptive protection. Expulsion risk is increased when inserted immediately after delivery; it appears to be increased with insertions after second-trimester abortion, based on limited data. Remove a partially expelled LILETTA. If expulsion has occurred, a new LILETTA may be inserted when there is reasonable certainty the patient is not pregnant.
Ovarian cysts may occur and are generally asymptomatic, but may be accompanied by pelvic or abdominal pain or dyspareunia. Evaluate persistent ovarian cysts.
In the LILETTA clinical trial, the most common adverse reactions (≥5% users) were vulvovaginal mycotic infections (20.2%), vaginal bacterial infections (19.2%), acne (15.5%), nausea or vomiting (10.5%), headache (10.1%), breast tenderness or pain (10.1%), abdominal discomfort or pain (10.0%), dyspareunia (9.6%), anxiety (9.6%), depression (9.1%), pelvic discomfort or pain (8.7%), dysmenorrhea (7.3%), mood changes (6.5%), back pain (6.5%), increased weight (6.1%), and vaginal discharge (5.8%).
Teach patients to recognize and immediately report signs or symptoms of the aforementioned conditions. Consider evaluating patients 4 to 6 weeks after LILETTA insertion and during routine care, or more often if clinically indicated. Check threads during each evaluation.
LILETTA® is a sterile, levonorgestrel-releasing intrauterine system indicated for prevention of pregnancy for up to 8 years. The system should be replaced after 8 years if continued use is desired.
Please see full Prescribing Information.